GlassScriptPhysician profile
Arlene Ledesma Yu
NPI 1144744772
$9,629.35
in general payments reported to CMS, 2019-2025
53 companies · $5,025 in 2025
The $5,025 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $4,605 · 2025: $5,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,098 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,098.02 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $251.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,697.96 | 2024-2025 | |
| Janssen Biotech, INC. | $1,027.58 | 2024-2025 | Tecvayli, Darzalex, Erleada |
| Pfizer INC. | $594.60 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $569.61 | 2024-2025 | Enhertu, Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $411.92 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $377.54 | 2024-2025 | Reblozyl, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $366.45 | 2024-2025 | Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $283.09 | 2024-2025 | Ninlaro, Alunbrig, Iclusig |
| Daiichi Sankyo INC. | $281.84 | 2024-2025 | Enhertu, Datroway |
| Sobi, INC | $264.08 | 2024-2025 | |
| Glaxosmithkline, LLC. | $218.20 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $198.92 | 2024-2025 | Vyloy, Xtandi, Xospata |
| Abbvie INC. | $189.86 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $185.09 | 2024-2025 | Xpovio |
| Taiho Oncology, INC. | $180.32 | 2024-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $168.14 | 2024-2025 | |
| Eisai INC. | $160.79 | 2024-2025 | |
| Incyte Corporation | $160.13 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Genzyme Corporation | $151.17 | 2024-2025 | |
| Genentech USA, INC. | $149.22 | 2024-2025 | Phesgo, Polivy, Venclexta |
| Gilead Sciences, INC. | $147.16 | 2024-2025 | Trodelvy |
| Blueprint Medicines Corporation | $144.41 | 2024 | Ayvakit |
| Exelixis INC. | $133.93 | 2024 | Cabometyx |
| Genmab U.S., INC. | $116.87 | 2024-2025 | Epkinly |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.82 | 2024-2025 | Gilotrif |
| Sun Pharmaceutical Industries INC. | $103.17 | 2024-2025 | |
| Array Biopharma INC | $99.69 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Stemline Therapeutics INC. | $97.80 | 2024-2025 | Orserdu |
| Boston Scientific Corporation | $88.07 | 2024-2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Lilly USA, LLC | $83.18 | 2024 | Verzenio, Jaypirca, Retevmo |
| Agios Pharmaceuticals, INC. | $74.98 | 2024-2025 | Pyrukynd |
| Regeneron Healthcare Solutions, INC. | $59.47 | 2024-2025 | Libtayo, Lynozyfic |
| Recordati_rare_diseases_inc. | $55.50 | 2025 | Sylvant, Enjaymo |
| Puma Biotechnology, INC. | $52.27 | 2025 | |
| Beigene USA, INC. | $46.41 | 2024-2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $45.92 | 2025 | Ultomiris |
| Acrotech Biopharma INC. | $45.92 | 2024 | Beleodaq |
| Coherus Oncology, INC. | $43.80 | 2025 | Loqtorzi |
| Mirati Therapeutics, INC. | $42.01 | 2024 | Krazati |
| Azurity Pharmaceuticals, INC. | $41.24 | 2025 | Danziten |
| Immunocore Limited | $39.41 | 2024 | Kimmtrak |
| Tersera Therapeutics LLC | $36.71 | 2025 | Zoladex |
| Kite Pharma, INC. | $30.03 | 2025 | Yescarta |
| Legend Biotech USA INC. | $28.98 | 2025 | Carvykti |
| Emd Serono, INC. | $28.92 | 2025 | |
| Kyowa Kirin, INC. | $28.74 | 2025 | |
| Beone Medicines USA, INC. | $28.30 | 2025 | Brukinsa |
| Syndax Pharmaceuticals, INC. | $28.22 | 2025 | |
| Adc Therapeutics America, INC. | $27.81 | 2024 | |
| Tolmar, INC. | $24.37 | 2024 | |
| Progenics Pharmaceuticals, INC. | $23.98 | 2024 | |
| Rigel Pharmaceuticals, INC. | $21.40 | 2024 | Tavalisse, Rezlidhia |
| Pharmaessentia USA Corporation | $18.35 | 2025 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arlene Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.